Skip to content

Protein Sources Urinary Stone Risk

The Effect of Protein Sources on Urinary Stone Risk

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05460247
Enrollment
14
Registered
2022-07-15
Start date
2022-10-30
Completion date
2023-07-30
Last updated
2023-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Stone Prevention

Keywords

Nephrolithiasis, Kidney stones, Protein

Brief summary

Prior studies have shown that the source of dietary protein can have a significant impact on urinary stone risk. However, whey and plant protein isolates have not been compared. This is an important distinction as protein supplements fortified foods are increasingly popular. Herein, we seek to investigate the effect of different protein supplements, in an otherwise identical diet, on urinary stone risk.

Detailed description

Each participant will receive a pre-made diet for 5 days at a time, for a total of 4 cycles. Previous studies have shown urine values reach a constant within the first 3 days. Diet will be a constant baseline diet representative of a standard Mediterranean diet. Participants will receive this diet to eat at home for 5 days with a supplemental protein shake at each meal (3 times a day). Participants will be required to drink 2.5-3 liters of fluid daily. Caffeine may be ingested as caffeine pills. Excessive exercise will be discouraged during the treatment phase. Diet will remain constant with respect to protein quantity and all other ingredients and will only change protein isolate source in supplemental protein shake. On days 4 and 5 of the diet, participants will be asked to collect two consecutive 24-hour urines. Between each 5-day diet phase, a flexible washout period will be allowed in which participants may eat a self-selected diet to take a break from standardized meals. Participants may resume the next phase diet on a day which is convenient for planned 24-hour urine collection at the end of that phase. The break period is to last no longer than 10 days.

Interventions

DIETARY_SUPPLEMENTProtein

Participants will receive a diet supplemented by the above protein

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Willing and able to complete the study 2. Healthy with no personal or family history of kidney stones

Exclusion criteria

1. Allergy to any protein isolates or menu items used in the study 2. History of calcium oxalate, cysteine, uric acid, or infection stones 3. Disorders of absorption: Celiac disease, Irritable Bowel Disease, chronic diarrhea, short gut 4. Systemic predisposition to stones: gout, congenital hyperuricemia, chronic diarrhea, insulin resistance, neoplastic disorders, hyperparathyroidism or renal tubular acidosis 5. Women who are currently pregnant or planning pregnancy within 2 years 6. Renal transplant recipient 7. Bedridden study participants (ECOG ≥ 3) 8. Uncorrected anatomical obstruction of the urinary tract 9. History of recurrent urinary tract infections (\> 3 urinary tract infections/year proven by urine culture) 10. Exclusions due to medication use: 1. Chronic use of lithium 2. Long-term glucocorticoid use (\> 7.5 mg prednisone daily for \> 30 days prior to enrollment) 3. Intake of narcotic medication on a daily basis for \>30 days prior to enrollment 4. Supplemental Vitamin C (\> 1 g daily) 5. Carbonic anhydrase inhibitors (acetazolamide, topiramate, zonisamide) 6. high dose calcium supplementation (\> 1,200 mg daily) 7. Medications that may crystallize in the urine (guaifenesin, sulfonamides, triamterene, and the protease inhibitors indinavir and nelfinavir). 11. Non-English Speakers 12. History of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) 13. Anatomical urologic abnormalities including ileal conduits, horseshoe kidney, megaureter or solitary kidney 14. Psychiatric conditions impairing compliance with the study 15. Vulnerable population (prisoner and/or cognitive impairment that the investigator feels will impact participant's ability to complete study activities)

Design outcomes

Primary

MeasureTime frameDescription
Urinary stone risk3 months after beginning study24 hour urine panel and supersaturation for Calcium Oxalate and Uric Acid
Calcium Oxalate Inhibitor activity3-6 months after beginning studymmol of Oxalate added before spontaneous precipitation

Countries

United States

Contacts

Primary ContactLinda Black
Blackl@wustl.edu3143936572

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026